natgillin/translations-raw huggingface dataset:
Serum levels of matrix metalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilage destruction were also decreased after adalimumab administration. 
Po uporabi adalimumaba se je zmanjšala tudi serumska raven matriksnih metaloproteinaz (MMP 1 in MMP 3), ki povzročajo remodeliranje tkiva, odgovorno za uničenje hrustanca.
• Keeping the syringe up, insert the syringe tip into the yellow syringe connector and twist the syringe as indicated by the arrow in the picture until firm. 
• Držite brizgo pokonci, vstavite konico igle v rumeni konektor za iglo in zasučite brizgo, kot kaže puščica na sliki, dokler ni trdno nameščena.
CI 95% for HR 
IZ 95 %
• Prepare the needle by partially peeling the package open from the end closest to the yellow syringe connector. 
• Pripravite iglo: delno odprite njeno ovojnino tako, da jo odlepite od konca, ki je najbližji rumenemu konektorju za brizgo.
You may see an air bubble, and that is okay. 
Morda boste opazili zračni mehurček.
Packs of: 
Pakiranja po:
Usually, Imraldi is used with methotrexate. 
Zdravilo Imraldi ponavadi uporabljamo z metotreksatom.
If the white plunger rod is pulled completely out of the syringe, discard the syringe and contact your Imraldi provider for a replacement. 
Če beli nosilec bata potegnete popolnoma iz brizge, brizgo zavrzite in se z dobaviteljem zdravila
Physicians should exercise caution when considering the use of Imraldi in patients with a history of recurring infection or with underlying conditions which may predispose patients to infections, including the use of concomitant immunosuppressive medications. 
Pri odločanju za uporabo zdravila Imraldi je potrebna previdnost pri bolnikih z anamnezo ponavljajoče se okužbe ali z osnovnimi boleznimi, ki lahko zvečajo nagnjenost k okužbam, vključno s sočasno uporabljenimi imunosupresivnimi zdravili.
Administration of Imraldi should be discontinued if a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy should be initiated until the infection is controlled. 
Če se bolniku pojavi nova resna okužba ali sepsa, je treba uporabo zdravila Imraldi prekiniti in uvesti ustrezno protimikrobno ali protimikotično zdravljenje, dokler okužba ni obvladana.
It is important that you tell your baby's doctors and other health care professionals about your Imraldi use during your pregnancy so they can decide when your baby should receive any vaccine. 
Zato je pomembno, da obvestite zdravnika vašega otroka in druge zdravstvene delavce, da ste med nosečnostjo prejemali zdravilo Imraldi, da se lahko odločijo, kdaj bo vaš otrok lahko prejel katerokoli cepivo.
• Push the white plunger rod all the way back in to push the liquid medication back into the vial. 
• Potisnite beli nosilec bata do konca nazaj, da boste tekoče zdravilo potisnili nazaj v vialo.
RA study III evaluated 619 patients with moderately to severely active rheumatoid arthritis who were ≥18 years old, and who had an ineffective response to methotrexate at doses of 12.5 to 25 mg or have been intolerant to 10 mg of methotrexate every week. 
V študiji revmatoidnega artritisa III je bilo ocenjeno 619 bolnikov z zmerno do zelo aktivnim revmatoidnim artritisom, starih ≥ 18 let, ki se niso učinkovito odzvali na odmerke metotreksata od 12,5 do 25 mg ali niso prenašali 10 mg metotreksata vsak teden.
• fatty liver (build up of fat in liver cells); 
• zamaščenost jeter (kopičenje maščobe v jetrnih celicah);
• lupus-like syndrome; 
• sindrom, podoben lupusu;
In RA studies I-IV, adalimumab -treated patients achieved statistically significant ACR 20 and 50 responses compared to placebo as early as one to two weeks after initiation of treatment. 
V študijah revmatoidnega artritisa I-IV so z adalimumabom zdravljeni bolniki v primerjavi s prejemniki placeba dosegli statistično značilen odziv 20 in 50 po ACR že en do dva tedna po začetku zdravljenja.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. 
Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev, se obrnite na zdravnika, preden boste vzeli to zdravilo.
The primary endpoint was the percent change from Baseline to week 12 in the number of active joints with arthritis (swelling not due to deformity or joints with loss of motion plus pain and/or tenderness), which was achieved with mean percent decrease of -62.6% (median percent change -88.9 %) in patients in the adalimumab group compared to -11.6% (median percent change -50.0 %) in patients in the placebo group. 
Primarni opazovani dogodek je bil odstotek spremembe od izhodiščne vrednosti do 12. tedna v številu aktivnih sklepov z artritisom (oteklina, ki ni nastala zaradi deformacije, ali sklepi z zmanjšano gibljivostjo ter bolečino in/ali občutljivostjo); slednji je bil dosežen s povprečnim zmanjšanjem za -62,6 % (mediana sprememba -88,9 %) pri skupini bolnikov, ki je prejemala adalimumab, v primerjavi z -11,6 % (mediana sprememba -50,0 %) v skupini bolnikov, ki je prejemala placebo.
Double-Blind Response at Week 12 
Odziv v 12. tednu
Seventy-nine (20.1%) patients were treated concomitantly with disease modifying anti − rheumatic drugs, and 37 (9.4%) patients with glucocorticoids. 
Devetinsedemdeset (20,1 %) bolnikov je sočasno dobivalo imunomodulacijska antirevmatična zdravila, 37 (9,4 %) bolnikov pa glukokortikoide.
Never reuse a syringe. 
Injekcijske brizge nikoli ne smete ponovno uporabiti.
Imraldi is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. 
Zdravilo Imraldi je indicirano za zdravljenje zmerne do hude kronične psoriaze v plakih pri odraslih bolnikih, ki so kandidati za sistemsko zdravljenje.
DO NOT put the clear needle cap back on the needle. 
NE NAMEŠČAJTE prozornega pokrovčka igle nazaj na iglo.
- This medicine has been prescribed for your child only. 
- Zdravilo je bilo predpisano vašemu otroku osebno in ga ne smete dajati drugim.
Rates of discontinuation of corticosteroids or immunomodulators are presented in Table 27. 
Stopnja prenehanja zdravljenja s kortikosteroidi ali imunomodulatorji je predstavljena v preglednici 27.
No ALT elevations ≥3 × ULN occurred in the Phase 3 trial of adalimumab in patients with polyarticular juvenile idiopathic arthritis who were 2 to <4 years. 
Zvišanja ALT ≥ 3 × ULN se niso pojavila v preskušanju faze 3 z adalimumabom pri bolnikih s poliartikularnim juvenilnim idiopatskim artritisom, ki so bili stari od 2 do < 4 leta.
The observed rate of non-melanoma skin cancers is approximately 9.6 per 1,000 patient years, and the observed rate of lymphomas is approximately 1.3 per 1,000 patient-years. 
Ugotovljeni delež nemelanomskih kožnih rakov je približno 9,6 na 1.000 bolnikov-let, ugotovljeni delež limfomov pa približno 1,3 na 1.000 bolnikov-let.
Adult Uveitis 
Uveitis pri odraslih
After you push the plunger all the way down, the needle will retract to help prevent needle stick injury. 
Ko potisnete bat povsem navzdol, se bo injekcijska igla pomaknila navznoter, kar pomaga preprečiti nehoten vbod.
Total Sharp Score 
Celotna Sharpova ocena
Over all 19 subjects, of which 11 of the baseline age group 4 to 12 and 8 of the baseline age group 13 to 17 years were treated 6 years or longer. 
Skupno je bilo 6 let ali več zdravljenih 19 preiskovancev, od tega 11 iz izhodiščne starostne skupine od 4 do 12 let in 8 iz izhodiščne starostne skupine od 13 do 17 let.
For patients who stayed on their randomised therapy, the mean (±SD) adalimumab trough concentrations at week 52 were 9.5±5.6 μg/ml for the Standard Dose group and 3.5±2.2 μg/ml for the Low Dose group. 
Pri bolnikih, ki so ostali na njihovi randomizirani terapiji, so bile povprečne najmanjše koncentracije adalimumaba v 52. tednu 9,5 ± 5,6 μg/ml v skupini s standardnim odmerkom in 3,5 ± 2,2 μg/ml v skupini z majhnim odmerkom.
Clinical remission Clinical response (CR-100) Patients in steroid-free remission for >=90 daysa 
Klinična remisija Klinični odziv (CR-100) Bolniki v remisiji brez steroidov ≥ 90 dnia
Available data suggest that the clinical response is usually achieved within 2-8 weeks of treatment. 
Podatki, ki so na voljo, kažejo, da je klinični odziv po navadi dosežen v 2-8 tednih zdravljenja.
• Keep the special container out of the sight and reach of children at all times. 
• Ta poseben vsebnik shranjujte ves čas nedosegljivo otrokom.
If your child takes Imraldi the risk of getting lymphoma, leukaemia, or other cancers may increase. 
Če vaš otrok jemlje zdravilo Imraldi, se mu lahko poveča tveganje za pojav limfoma, levkemije ali drugih vrst raka.
• Children from 2 years of age with chronic non-infectious uveitis with inflammation affecting the front of the eye 
• otrok, starejših od 2 let, s kroničnim neinfekcijskim uveitisom, kjer vnetje prizadene sprednji del očesa.
The pivotal controlled studies involved 6,089 patients receiving adalimumab and 3,801 patients receiving placebo or active comparator during the controlled period. 
Kontrolirane študije, ki podpirajo vlogo za pridobitev dovoljenja za promet, so vključevale 6.089 bolnikov, ki so med kontroliranim obdobjem dobivali adalimumab, in 3.801 bolnikov, ki so med tem obdobjem dobivali placebo ali primerjalno učinkovino.
• Do not give Imraldi to children with polyarticular juvenile idiopathic arthritis below the age of 
• Zdravila Imraldi ne smete dati otroku s poliartikularnim juvenilnim idiopatskim artritisom, če je star manj kot 2 leti.
A patient who requires surgery while on Imraldi should be closely monitored for infections, and appropriate actions should be taken. 
Bolnika, ki med zdravljenjem z zdravilom Imraldi potrebuje operacijo, je treba natančno nadzirati glede okužb in ustrezno ukrepati.
There is no button on your pre-filled pen. 
Na vašem napolnjenem injekcijskem peresniku ni gumba.
In the open-label extension, improvement in the signs and symptoms was maintained with adalimumab therapy through week 156. 
Pri odprtih podaljšanih študijah se je pri zdravljenju z adalimumabom izboljšanje znakov in simptomov ohranjalo do 156. tedna.
• Pull the needle package off, but DO NOT remove the clear needle cap. 
• Snemite ovojnino igle, vendar NE ODSTRANITE prozornega pokrovčka igle.
Name and address of the manufacturer(s) of the biological active substance(s) 
Ime in naslov izdelovalca (izdelovalcev) biološke učinkovine (učinkovin) Biogen Inc.
Table 28 Response, Remission and Mucosal Healing in Study UC-II (Percent of Patients) 
Odziv, remisija in celjenje sluznice v študiji UC-II (odstotek bolnikov)
The rate of pregnancies ending with at least one live born infant with a major birth defect was 6/69 (8.7 %) in the adalimumab-treated women with RA and 5/74 (6.8 %) in the untreated women with RA (unadjusted OR 1.31, 95 % CI 0.38-4.52) and 16/152 (10.5 %) in the adalimumab-treated women with CD and 3/32 (9.4 %) in the untreated women with CD (unadjusted OR 1.14, 95 % CI 0.31-4.16). 
Razmerje nosečnosti, ki so se končale vsaj z enim živorojenim otrokom z večjim defektom ob rojstvu je bilo 6/69 (8,7 %) pri nosečnicah, zdravljenih z adalimumabom z RA, in 5/74 (6,8 %) pri nezdravljenih nosečnicah z RA (neprilagojeno razmerje obetov 1.31, 95 % interval zaupanja 0.38-4.52), ter 16/152 (10,5 %) pri nosečnicah, zdravljenih z adalimumabom s CB, in 3/32 (9,4 %) pri nezdravljenih nosečnicah s CB (neprilagojeno razmerje obetov 1.14, 95 % interval zaupanja 0.31-4.16).
The conduct and results of these tests should be recorded on your child's Patient Reminder Card. 
Izvedbo in rezultate teh preiskav je treba zabeležiti na otrokovi Opozorilni kartici za bolnika.
Prescribers should exercise caution in considering the use of Imraldi in patients with pre-existing or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of Imraldi should be considered if any of these disorders develop. 
Pri odločanju za uporabo zdravila Imraldi pri bolnikih z že prej obstoječimi ali nedavno nastalimi demielinizirajočimi boleznimi osrednjega ali perifernega živčevja je potrebna previdnost; če se razvije katera od teh bolezni, je treba razmisliti o prenehanju zdravljenja z zdravilom Imraldi.
79 (73.1)a, b a p<0.001 adalimumab vs. placebo b p<0.001 adalimumab vs. methotrexate c p<0.01 adalimumab vs. placebo d p<0.05 adalimumab vs. methotrexate 
79 (73,1)a, b a p < 0,001 adalimumab v primerjavi s placebom b p < 0,001 adalimumab v primerjavi z metotreksatom c p < 0,01 adalimumab v primerjavi s placebom d p < 0,05 adalimumab v primerjavi z metotreksatom
Women of childbearing potential should consider the use of adequate contraception to prevent pregnancy and continue its use for at least five months after the last Imraldi treatment. 
Ženske v rodni dobi morajo premisliti o uporabi ustrezne kontracepcijske zaščite za preprečitev nosečnosti in z njo nadaljevati vsaj še pet mesecev po zadnjem zdravljenju z zdravilom Imraldi.
673 patients with active nr-axSpA (mean baseline disease activity [BASDAI] was 7.0) who had an inadequate response to ≥ 2 NSAIDs, or an intolerance to or a contraindication for NSAIDs enrolled into the open-label period of study nr-axSpA II during which they received adalimumab 40 mg eow for 28 weeks. 
673 bolnikov z aktivnim nr-axSpA (srednja vrednost aktivnosti bolezni [BASDAI] je bila 7,0), ki so nezadostno reagirali na vsaj dva NSAID ali niso prenašali NSAID ali s kontraindikacijo za NSAID, je bilo vključenih v odprto fazo študije nr-axSpA II, v kateri so prejemali zdravilo adalimumab 40 mg vsak drugi teden 28 tednov.
• Use your other hand to flip the pink needle cover down toward the syringe. 
• Z drugo roko obrnite rožnati pokrovček igle dol proti brizgi.
How to use Imraldi 
Kako uporabljati zdravilo Imraldi
• Gently flip the pink needle cover up, over the needle and snap into place and set the syringe with needle on the work surface. 
• Previdno obrnite rožnati pokrovček igle gor, čez iglo, da se zaskoči na mesto, in položite brizgo z iglo na delovno površino.
RA study II evaluated 544 patients with moderately to severely active rheumatoid arthritis who were ≥18 years old and had failed therapy with at least one disease-modifying, anti-rheumatic drugs. 
V študiji revmatoidnega artritisa II je bilo ocenjeno 544 bolnikov z zmerno do hudo aktivnim revmatoidnim artritisom, starih ≥ 18 let, pri katerih zdravljenje z vsaj enim imunomodulirajočim antirevmatičnim zdravilom ni bilo uspešno.
Of the patients who lost adequate response after re-randomisation to placebo who then enrolled into the open-label extension trial, 38 % (25/66) and 55 % (36/66) regained PASI 75 response after 12 and 24 weeks of re-treatment, respectively. 
Med bolniki, ki so izgubili ustrezen odziv ob ponovni randomizaciji na placebo med podaljšanim odprtim preskušanjem, je po 12 tednih ponovne terapije PASI 75 znova doseglo 38 % (25/66), po 24 tednih pa 55 % (36/66) bolnikov.
Rates of discontinuation of corticosteroids or immunomodulators are presented in Table 21. 
Stopnja prenehanja zdravljenja s kortikosteroidi ali imunomodulatorji je predstavljena v preglednici 21.
- Your doctor will also give you a Patient Reminder Card, which contains important safety information that you need to be aware of before your child is given Imraldi and during treatment with Imraldi. 
- Zdravnik vam bo dal tudi Opozorilno kartico za bolnika, ki vsebuje pomembne varnostne informacije, s katerimi morate biti seznanjeni, preden vaš otrok prejme zdravilo Imraldi in med zdravljenjem z njim.
solution for injection 1 vial 
raztopina za injiciranje 1 viala
Imraldi works by reducing this inflammation. 
Zdravilo Imraldi deluje tako, da zmanjša tako vnetje.
No ALT elevations ≥3 × ULN occurred in the Phase 3 trial of adalimumab in paediatric patients with plaque psoriasis. 
Do nobenih zvišanj ALT ≥ 3 × ULN ni prišlo v preskušanju faze 3 z adalimumabom pri pediatričnih bolnikih s psoriazo v plakih.
Neurologic evaluation should be performed in patients with non-infectious intermediate uveitis prior to the initiation of Imraldi therapy and regularly during treatment to assess for pre-existing or developing central demyelinating disorders. 
Pri bolnikih z neinfekcijskim intermediarnim uveitisom je treba pred začetkom zdravljenja z zdravilom Imraldi in redno med zdravljenjem opravljati nevrološko oceno, da se oceni že obstoječe ali razvijajoče se demielinizirajoče bolezni osrednjega živčevja.
Imraldi is used to treat children from 2 years of age with chronic non-infectious uveitis with inflammation affecting the front of the eye. 
Zdravilo Imraldi se uporablja za zdravljenje otrok, starejših od 2 let, s kroničnim neinfekcijskim uveitisom, kjer vnetje prizadene sprednji del očesa.
Week 52 Open-label 
52. teden Odprta
- Your doctor will also give you a Patient Reminder Card, which contains important safety information that you need to be aware of before you are given Imraldi and during treatment with Imraldi. 
- Zdravnik vam bo dal tudi Opozorilno kartico za bolnika, ki vsebuje pomembne varnostne informacije, s katerimi morate biti seznanjeni, preden prejmete zdravilo Imraldi in med zdravljenjem z njim.
If you use more Imraldi than you should 
Če ste uporabili večji odmerek zdravila Imraldi, kot bi smeli
At week 12, a significantly higher proportion of patients in study HS-II experienced a clinically relevant decrease in HS-related skin pain (see Table 21). 
V 12. tednu je statistično pomembno večji delež bolnikov v študiji HS-II občutil klinično pomembno zmanjšanje bolečine na koži, povezane s HS (glejte preglednico 21).
At week 12, a significantly higher proportion of patients in study HS-II experienced a clinically relevant decrease in HS-related skin pain (see Table 17). 
V 12. tednu je statistično pomembno večji delež bolnikov v študiji HS-II občutil klinično pomembno zmanjšanje bolečine na koži, povezane s HS (glejte preglednico 17).
Among patients who were at least partial responders at week 12, and who received continuous weekly adalimumab therapy, the HiSCR rate at week 48 was 68.3% and at Week 96 was 65.1%. 
Pri bolnikih z vsaj delnim odzivom na adalimumab v odmerku 40 mg v 12. tednu, in ki so prejemali neprekinjeno tedensko terapijo adalimumaba vsak teden, je bila stopnja kliničnega odziva (HiSCR) v 48. tednu 68,3 %, v 96. tednu pa 65,1 %.
Place your pre-filled pen and alcohol pads on a clean, dry surface. 
Napolnjen injekcijski peresnik in alkoholne zložence položite na čisto, suho površino.
A total of 347 stable responders participated in a withdrawal and retreatment evaluation in an open-label extension study. 
V odprti podaljšani študiji je v oceni prenehanja uporabe in ponovnega zdravljenja sodelovalo skupno 347 stabilnih odzivnih bolnikov.
Your doctor will decide if your child should receive Imraldi. 
On se bo odločil, ali lahko vaš otrok dobiva zdravilo Imraldi.
Of 542 patients who were randomised to adalimumab 40 mg every other week, 170 patients continued on adalimumab 40 mg every other week for 10 years. 
Od 542 bolnikov, ki so bili randomizirani na 40 mg adalimumaba vsak drugi teden, jih je 170 nadaljevalo zdravljenje s 40 mg adalimumaba vsak drugi teden še 10 let.
If your doctor considers that methotrexate is inappropriate, Imraldi can be given alone. 
Če zdravnik meni, da metotreksat ni primeren, lahko zdravilo Imraldi dobivate samo.
It is important that you tell your baby's doctors and other health care professionals about your Imraldi use during your pregnancy before the baby receives any vaccine (for more information on vaccines see the “Warnings and precautions” section). 
Pomembno je, da obvestite zdravnika vašega dojenčka in druge zdravstvene delavce, da ste med nosečnostjo prejemali zdravilo Imraldi, preden bo vaš dojenček prejel katerokoli cepivo (za več informacij o cepljenju glejte poglavje "Opozorila in previdnostni ukrepi").
1 sterile injection syringe 1 sterile needle 1 sterile vial adapter 2 alcohol pads 
1 sterilno injekcijsko brizgo 1 sterilno iglo 1 sterilen adapter za vialo
Tell your doctor if your child is taking azathioprine or mercaptopurine with Imraldi. 
Povejte zdravniku, če vaš otrok prejema azatioprin ali merkaptopurin sočasno z zdravilom Imraldi.
The safety and efficacy of adalimumab were assessed in randomised, double-blind, placebo-controlled studies and an open-label extension study in adult patients with moderate to severe hidradenitis suppurativa (HS) who were intolerant, had a contraindication or an inadequate response to at least a 3month trial of systemic antibiotic therapy. 
Varnost in učinkovitost adalimumaba so raziskali v randomiziranih, dvojno slepih študijah, kontroliranih s placebom, in v odprti podaljšani študiji pri odraslih bolnikih z zmerno do hudo obliko hidradenitis suppurativa (HS), ki imajo intoleranco, kontraindikacijo ali se ne odzovejo zadovoljivo pri vsaj 3-mesečnem preskušanju sistemske antibiotične terapije.
In the open-label lead in phase (OL LI) patients were stratified into two groups, MTX (methotrexate)-treated or non-MTX- treated. 
V odprti uvajalni fazi so bolnike stratificirali v dve skupini: zdravljene z metotreksatom in zdravljene brez metotreksata.
In rheumatoid arthritis, methotrexate is continued while using Imraldi. 
Pri revmatoidnem artritisu se uporaba metotreksata med uporabo zdravila Imraldi nadaljuje.
Adalimumab 40 mg every other week was assessed in 393 patients in two randomised, 24 week double blind, placebo − controlled studies in patients with active ankylosing spondylitis (mean baseline score of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.3 in all groups) who have had an inadequate response to conventional therapy. 
40 mg adalimumaba vsak drugi teden so ocenili v dveh randomiziranih 24-tedenskih dvojno slepih, s placebom kontroliranih študijah pri 393 bolnikih z aktivnim ankilozirajočim spondilitisom (povprečna izhodiščna ocena aktivnosti bolezni [indeks BASDAI (Bathov indeks bolezenske aktivnosti ankilozirajočega spondilitisa - Bath Ankylosing Spondylitis Disease Activity Index)] je bil v vseh skupinah 6,3), ki se niso odzvali ustrezno na konvencionalno terapijo.
The decision to stop using Imraldi should be discussed with your doctor. 
O odločitvi, da bi prenehali uporabljati zdravilo Imraldi, se morate posvetovati z zdravnikom.
Upon completion of the first 52 weeks, 457 patients enrolled in an open-label extension phase in which 40 mg of adalimumab/MTX was administered every other week up to 10 years. 
Po zaključenih prvih 52 tednih so 457 bolnikov vključili v odprto nadaljevalno fazo, med katero so dobivali 40 mg adalimumaba/MTX vsak drugi teden v obdobju do 10 let.
If you accidentally inject a larger amount of Imraldi liquid, or if you inject Imraldi more frequently than you should, call your child's doctor or pharmacist and explain that your child has taken more. 
Če pomotoma injicirate več tekočine z zdravilom Imraldi ali pa zdravilo Imraldi injicirate pogosteje, kot bi smeli, se morate posvetovati z zdravnikom svojega otroka ali farmacevtom in razložiti, da je vaš otrok dobil večji odmerek.
If your doctor determines that methotrexate is inappropriate, Imraldi can be given alone. 
Če zdravnik ugotovi, da metotreksat ni primeren, lahko zdravilo Imraldi dobivate samo.
Among patients whose adalimumab treatment was withdrawn at week 12 in studies HS-I and HS-II, the HiSCR rate 12 weeks after re-introduction of adalimumab 40 mg weekly returned to levels similar to that observed before withdrawal (56.0 %). 
Med bolniki, pri katerih je bilo zdravljenje z adalimumabom ukinjeno v 12. tednu v študijah HS-I in HS-II, se je po ponovni uvedbi 40 mg adalimumaba enkrat na teden raven kliničnega odziva (HiSCR) vrnila na podobno raven, kot so jo opazili pred ukinitvijo (56,0 %).
• Tell your doctor if you reside or travel in regions where fungal infections such as histoplasmosis, coccidioidomycosis or blastomycosis are endemic. 
• Zdravniku morate povedati, če živite na območju ali potujete v predele, kjer so endemične glivične okužbe, npr. histoplazmoza, kokcidioidomikoza ali blastomikoza.
After two further weeks, continue with a dose of 40 mg every week or 80 mg every other week, as prescribed by your doctor. 
Čez nadaljnja dva tedna nadaljujte z odmerkom 40 mg vsak teden ali 80 mg vsak drugi teden, kot vam je predpisal zdravnik.